New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2013
10:45 EDTTHRX, THRX, GSK, GSK, VRX, VRX, DEPO, DEPO, FLML, FLML, CELG, CELG, ONXX, ONXX, FRX, FRX, AVEO, AVEOWashington Analysis healthcare analyst holds analyst/industry conference call
Healthcare Analyst Loss discusses top FDA issues which include upcoming FDA meetings, FDA rules and initiatives and PDUFA dates (THRX, GSK, VRX, DEPO, FLML, CELG, ONXX, FRX and AVEO) on an Analyst/Industry conference call to be held on May 1 at 11 am.
News For THRX;GSK;VRX;DEPO;FLML;CELG;ONXX;FRX;AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
08:05 EDTFLMLFlamel backs FY15 product revenue $170M-$185M, consensus $187.64M
Subscribe for More Information
08:04 EDTFLMLFlamel reports Q1 EPS 27c, consensus 31c
Subscribe for More Information
May 14, 2015
15:01 EDTFLMLNotable companies reporting before tomorrow's open
Subscribe for More Information
11:11 EDTCELGAnalysts divided on significance of Celgene blood cancer drug data
Subscribe for More Information
09:43 EDTFLMLFlamel management to meet with SunTrust
Subscribe for More Information
May 13, 2015
17:42 EDTCELGCelgene announces over 55 blood, solid tumor cancer study presentations at ASCO
Subscribe for More Information
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
08:43 EDTDEPODepomed weakness overdone, says Roth Capital
Subscribe for More Information
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
May 12, 2015
12:44 EDTDEPODepomed selloff an overreaction, says Roth Capital
Subscribe for More Information
12:24 EDTDEPODepomed upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
09:20 EDTDEPOOn The Fly: Pre-market Movers
Subscribe for More Information
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
16:35 EDTDEPODepomed sees 2015 sales $310M-$335M, consensus $305M
Subscribe for More Information
16:34 EDTDEPODepomed reports Q1 adjusted EPS (13c), consensus 1c
Subscribe for More Information
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
May 8, 2015
11:39 EDTFLMLFlamel jumps after competitors scrap narcolepsy drug development
Subscribe for More Information
08:53 EDTFLMLFlamel has positive read through from competitor news, says JMP Securities
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use